Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of nivobotulinumtoxinA for glabellar lines with or without concurrent lateral canthal line treatment
2014-005301-21Phase 3Unknown
- Sponsor
- Allergan
- Start
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glabellar furrowing and lateral canthal rhytides comparing nivobotulinumtoxinA with placebo (2 arms). Primary endpoint: Coprimary efficacy endpoint. Status: unknown.
02
Drugs
nivobotulinumtoxinA
03
Conditions
glabellar furrowinglateral canthal rhytides
Beyond the preview
Go deeper on 2014-005301-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005301-21.